Trending stocks today
Bristol Myers Squibb (BMY-N)
NYSE:BMY
50.45
5.18
(11.44%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
U.S inflation hot, GDP cool, Wall Street down, TSX flatMicrosoft hits highs, markets riseStocks extend slide post-FedThis summary was created by AI, based on 11 opinions in the last 12 months.
Experts have mixed opinions on Bristol Myers Squibb (BMY-N). Some are optimistic about the company's AI potential and strong dividend, while others express concerns about patent cliffs and the need for a turnaround. The company's recent acquisitions and partnerships in the pharmaceutical industry are seen as positive moves to address challenges. Despite differing views on the stock's performance, there is a consensus that it holds potential but also faces significant hurdles in the coming years.
N/A
Owned
His whole mantra is to buy good companies that are getting better. He wants to have a strong fundamental view, and he wants the market to show that it's agreeing with him -- he doesn't want to be alone in the woods in a good market, not participating.
Problem is a fair bit of debt, low growth. In a market like this, you only need 20 companies to get a broadly diversified portfolio. Don't need to take on the risk of this one. Avoid.
It will need a lot of time to turn around. It hit bottom when it touched a 5.75% dividend yield. You won't see good news here until 2029 or 2030.
Dow 7% in May. Lots of struggle in the healthcare space. Will sell.
The market lacks patience for them to get into AI, though he disagrees and the dividend is good.
A lot of their big drugs are coming off patent, and they will need 5 years to turn around. Meanwhile, collect the 5% dividend as you wait. Be patient. He prefers Eli Lilly.
Down 23% in the past 6 months. Pays a 5% dividend. Be patient and give the current CEO a chance to turn things around.
Big on immune oncology and cardio. Technically doesn't look great, but eventually "the train will come along and collect the mail bag". Makes a ton of $$ in NA. Wide moat. Concerns about pipeline, but he thinks it's pretty good. Limited downside. Yield is 4.9%.
Good pricing power. Because products are so specialized, FDA puts them on sort of a fast track.
In the past quarter, They recently bought 3 companies, including Mirati, a small oncology company, and Karuna who may develop a wonder drug to treat schizophrenia. BMY needs to buy companies, because their top 3 drugs face steep patent cliffs, like a blood-clot drug, accounting for over 61% of 2023 (Jan-Sept)'s sales.
The company has partnered with a Chinese pharma company for a new drug to lung and breast cancer patients. They will have exclusive rights outside of China. It trades at 13x earnings and supports a ROE of 26%. It has a good dividend, backed by a payout ratio under 60% of cash flow. The company has been prudentially using some cash reserves to aggressively buy back shares and retire debt. We recommend placing a stop at $44, looking to achieve $63 -- upside potential of 23%. Yield 4.4%
(Analysts’ price target is $62.82)Disagrees with today's downgrade. BMY will produce $75 billion free cash flow over the next 5 years, which will transform them.
They don't have the drug pipeline that they used to have. Also, don't buy a stock only for the dividend.
Investors have given up on drug stocks, including BMY, but he won't. You must own a drug stock in your portfolio.
It has some real challenges from 2026 to 2030 when some of their drugs will come off patents. They will need to fill their pipeline. This is reflected in the 8X earnings multiple. As for Amgen, it has defensive characteristics but we need to make sure they execute their plans.
Bristol Myers Squibb(BMY-N) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 4
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 5
Total Signals / Votes : 9
Bristol Myers Squibb(BMY-N) Frequently Asked Questions
What is Bristol Myers Squibb stock symbol?
Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N
Is Bristol Myers Squibb a buy or a sell?
In the last year, 9 stock analysts published opinions about BMY-N. 4 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.
Is Bristol Myers Squibb a good investment or a top pick?
Bristol Myers Squibb was recommended as a Top Pick by on . Read the latest stock experts ratings for Bristol Myers Squibb.
Why is Bristol Myers Squibb stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Bristol Myers Squibb worth watching?
9 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.
What is Bristol Myers Squibb stock price?
On 2024-07-26, Bristol Myers Squibb (BMY-N) stock closed at a price of $50.45.
They just reported a Q2 beat. It hasn't performed well, but is finally rebounding a little. Their product pipeline will be good for the next few years.